scholarly journals One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody

Blood ◽  
1993 ◽  
Vol 82 (8) ◽  
pp. 2485-2493 ◽  
Author(s):  
U Galili ◽  
F Anaraki ◽  
A Thall ◽  
C Hill-Black ◽  
M Radic
Keyword(s):  
B Lymphocytes ◽  
Blood Group ◽  
Enzyme Linked Immunosorbent Assay ◽  
Barr Virus ◽  
Effective System ◽  
Group A ◽  
Igh Gene Rearrangement ◽  
Epstein Barr ◽  
B Lymphoid ◽  
Group B

The natural anti-Gal antibody constitutes 1% of circulating IgG in humans and interacts specifically with the carbohydrate epitope Gal alpha 1–3Gal beta 1–4GlcNAc-R (the alpha-galactosyl epitope). In view of the unusually large amounts of this antibody in the serum, it was of interest to determine the proportion of circulating B lymphocytes capable of synthesizing anti-Gal. For this purpose, blood B lymphocytes were incubated with Epstein-Barr virus (EBV) and plated in microtiter wells. Proliferation of the EBV transformed B lymphocytes was readily visible after 3 weeks of incubation. The supernatants from wells containing proliferating B-lymphoid clones were assayed for anti-Gal by an agglutination assay with rabbit red blood cells and the specificity of the agglutinating antibodies was further confirmed by their interaction with synthetic oligosaccharides and by enzyme-linked immunosorbent assay with glycoproteins. Approximately 5% of the wells contained anti-Gal antibodies. Limiting dilution studies and IgH gene rearrangement patterns suggested that each well contained an average of five proliferating B-lymphoid clones. Thus, it is concluded that approximately 1% of circulating B lymphocytes are capable of producing anti-Gal. The proportion of anti-Gal--producing lymphoid clones exceeds by fourfold that of clones producing anti-blood group A or anti-blood group B antibodies. Individual anti-Gal clones display fine variations in their combining site, as indicated by their differential interaction with alpha-galactosyl epitopes on glycolipids and on N-linked carbohydrate chains of glycoproteins. The high frequency of precursor B lymphocytes capable of producing anti-Gal, found in every individual and the restricted specificity of this antibody to alpha-galactosyl epitopes, potentially makes anti-Gal--producing lymphocytes an effective system for studying human Ig genes involved in the natural immune response to structurally defined haptens.

One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody

Blood ◽  
1993 ◽  
Vol 82 (8) ◽  
pp. 2485-2493 ◽  
Author(s):  
U Galili ◽  
F Anaraki ◽  
A Thall ◽  
C Hill-Black ◽  
M Radic
Keyword(s):  
B Lymphocytes ◽  
Blood Group ◽  
Enzyme Linked Immunosorbent Assay ◽  
Barr Virus ◽  
Effective System ◽  
Group A ◽  
Igh Gene Rearrangement ◽  
Epstein Barr ◽  
B Lymphoid ◽  
Group B

Abstract The natural anti-Gal antibody constitutes 1% of circulating IgG in humans and interacts specifically with the carbohydrate epitope Gal alpha 1–3Gal beta 1–4GlcNAc-R (the alpha-galactosyl epitope). In view of the unusually large amounts of this antibody in the serum, it was of interest to determine the proportion of circulating B lymphocytes capable of synthesizing anti-Gal. For this purpose, blood B lymphocytes were incubated with Epstein-Barr virus (EBV) and plated in microtiter wells. Proliferation of the EBV transformed B lymphocytes was readily visible after 3 weeks of incubation. The supernatants from wells containing proliferating B-lymphoid clones were assayed for anti-Gal by an agglutination assay with rabbit red blood cells and the specificity of the agglutinating antibodies was further confirmed by their interaction with synthetic oligosaccharides and by enzyme-linked immunosorbent assay with glycoproteins. Approximately 5% of the wells contained anti-Gal antibodies. Limiting dilution studies and IgH gene rearrangement patterns suggested that each well contained an average of five proliferating B-lymphoid clones. Thus, it is concluded that approximately 1% of circulating B lymphocytes are capable of producing anti-Gal. The proportion of anti-Gal--producing lymphoid clones exceeds by fourfold that of clones producing anti-blood group A or anti-blood group B antibodies. Individual anti-Gal clones display fine variations in their combining site, as indicated by their differential interaction with alpha-galactosyl epitopes on glycolipids and on N-linked carbohydrate chains of glycoproteins. The high frequency of precursor B lymphocytes capable of producing anti-Gal, found in every individual and the restricted specificity of this antibody to alpha-galactosyl epitopes, potentially makes anti-Gal--producing lymphocytes an effective system for studying human Ig genes involved in the natural immune response to structurally defined haptens.

scholarly journals Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1003-1005
Author(s):  
HJ Lawrence ◽  
VC Broudy ◽  
RE Magenis ◽  
S Olson ◽  
D Tomar ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Progenitor Cell ◽  
Epstein Barr Virus ◽  
Peripheral Blood Lymphocytes ◽  
Lymphoid Cells ◽  
Barr Virus ◽  
Karyotypic Abnormality ◽  
Cytogenetic Evidence ◽  
Epstein Barr ◽  
B Lymphoid

We studied the cellular distribution of an unusual chromosomal abnormality, an interstitial deletion of the long arm of chromosome 13, in the peripheral blood lymphocytes of two patients with acquired idiopathic sideroblastic anemia (AISA). We found no metaphases containing the 13q- abnormality in preparations of phytohemagglutinin (PHA)-stimulated lymphocytes from either patient. In both cases, however, some metaphases from Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines contained the clonal karyotypic abnormality. These observations indicate that B lymphocytes but not T cells are expressed as members of the clonal cohort of cells. Our results strongly suggest that the initial pathogenetic events that led to expansion of the 13q- clone occurred in a progenitor cell capable of giving rise to both hematopoietic and B lymphoid cells.

Hyperimmune human ABO blood-typing sera: reactivity with murine laminin and cytotoxicity for metastatic murine tumour cells

1983 ◽  
Vol 59 (1) ◽  
pp. 245-256
Author(s):  
J.P. McCoy ◽  
D. Schrier ◽  
E.J. Lovett ◽  
W.J. Judd ◽  
J. Varani
Keyword(s):  
Blood Group ◽  
Water Soluble ◽  
Antigenic Determinants ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Typing ◽  
Metastatic Cells ◽  
End Groups ◽  
Group A ◽  
Murine Fibrosarcoma ◽  
Group B

Commercially prepared ABO blood-typing antisera have been tested for their ability to bind to murine laminin and their cytotoxic effects upon high and low metastatic variants of a murine fibrosarcoma. Previous studies have shown that alpha-D-galactopyranosyl end-groups comprise the major antigenic determinants on type B erythrocytes and that these same end-groups are present on murine laminin purified from the EHS sarcoma and on a laminin-like glycoprotein on the surface of the high, but not low, metastatic fibrosarcoma cells. In the present study we found that all sera containing anti-B activity were cytotoxic to the high, but not the low, metastatic cells and that all of these sera reacted strongly against immobilized murine laminin in an enzyme-linked immunosorbent assay. Sera lacking anti-B activity, i.e. anti-A antisera, were much less cytotoxic to either cell line and three of the four anti-A sera did not bind to murine laminin. The laminin reactivity and cytotoxic effect of the anti-B sera were specifically abrogated by preincubation of the sera with water-soluble blood group B substance or with murine laminin but not with water-soluble blood group A substance.

scholarly journals Significance of confirming Epstein-Barr virus nuclear antibody as tumor marker

2007 ◽  
Vol 64 (7) ◽  
pp. 459-462 ◽  
Author(s):  
Svetlana Stosic-Divjak ◽  
Vojko Djukic ◽  
Ivan Boricic ◽  
Alek Racic ◽  
Isidora Divjak ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Blood Donors ◽  
Malignant Tumors ◽  
Barr Virus ◽  
Group A ◽  
Causal Treatment ◽  
Nasopharyngeal Tumors ◽  
Epstein Barr ◽  
Group B ◽  
Group D

Backgrounnd/Aim. Study of the association between Epstein-Barr virus (EBV) and the tumors of the nasopharynx renders an opportunity to introduce causal treatment. Already have been proven the anti-EBV (anti-Epstein-Barr nucleus antigene) antibodies in the blood serum of the patients infected with EBV, while over 91% of the patients with nasopharyngeal malignant tumors also have a detectable anti-EBV marker. The aim of this research was to determine if there were anti-EBV antibodies in the serum of the patients with the already verified nasopharyngeal malignant tumors, and, if there were, to determine the quantitative ratio to the values in the serum of the healthy controls. Methods. The study involved 74 individuals in the period from 1994?2001 divided into four groups: group A counting 11 patients with undifferentiated carcinome of nasopharyngeal type (UCNT); group B counting 25 patients with UCNT Xray treated at least three years before the onset of the study; group C including 28 healthy subjecets (blood donors), and the group D with 10 patients with planocellular nasopharyngeal carcinoma. Serologic diagnostics of the patients serum was performed using the techniques of Reedman and Klein for the detection of anti-EBV antibodies in the serum. Results. The presence of the statistically significantly higher values of the mean geometric titer (MGT) of the anti- EBNA antibodies was determined in 36 patients with histologically verified UCNT as compared with the control groups including 10 patients with planocellular carcinomas of the nasopharynx and 28 blood donors. Presented were anti-EBNA titers with 95% confidence interval for any participants according to the Hoo clinical classification of nasopharyngeal tumors, as well as according to the fact if they had been radiotreated within the previous three years. Conclusion. The results of this study confirm the conclusions of the recent literature on the possible etiopathogenesis of nasopharyngeal tumors and the use of viral anti-EBNA antibodies as viral markers in the diagnostics of UCNT diseases. .

Use of Plasma Epstein-Barr virus DNA Monitoring as a Tumor Marker in follow-up of Patients with Nasopharyngeal Carcinoma: Preliminary Results and Report of two Cases

2007 ◽  
Vol 22 (3) ◽  
pp. 194-199 ◽  
Author(s):  
E. Özyar ◽  
M. Gültekin ◽  
A. Alp ◽  
G. Hasçelik ◽  
Ö. Ugur ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Nasopharyngeal Cancer ◽  
Barr Virus ◽  
Group A ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Group B

Recent studies suggest that plasma Epstein-Barr virus (EBV) DNA may reflect tumor burden in patients with nasopharyngeal cancer. A prospective study was initiated to investigate this correlation in 125 patients (34 pretreatment [Group A], 78 in remission [Group B] and 13 relapsed [Group C]) and 19 healthy controls. In group A, EBV DNA was detected in plasma samples of 24 (70%) patients. In Group B, EBV DNA was detected in 7 patients (range 77–13,731 copies/mL) and further imaging in all but one of these patients revealed active disease confirmed by ultrasound-guided fine-needle biopsy. There was only one false-positive case; this patient is currently under follow-up. Here we describe 2 of the 7 patients with detectable plasma EBV DNA in whom recurrence was documented by PET scan during follow-up. Our results showed that in group B the positive predictive value of quantitative analysis of plasma EBV DNA was 85%. Quantitative analysis of EBV DNA in plasma seems to become an integral part of screening, staging, monitoring, and prediction of relapse in patients with nasopharyngeal carcinoma. However, previous studies cannot be considered definitive and more reports on the use of this technique are urgently needed from both endemic and non-endemic regions.

scholarly journals Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1003-1005 ◽  
Author(s):  
HJ Lawrence ◽  
VC Broudy ◽  
RE Magenis ◽  
S Olson ◽  
D Tomar ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Progenitor Cell ◽  
Epstein Barr Virus ◽  
Peripheral Blood Lymphocytes ◽  
Lymphoid Cells ◽  
Barr Virus ◽  
Karyotypic Abnormality ◽  
Cytogenetic Evidence ◽  
Epstein Barr ◽  
B Lymphoid

Abstract We studied the cellular distribution of an unusual chromosomal abnormality, an interstitial deletion of the long arm of chromosome 13, in the peripheral blood lymphocytes of two patients with acquired idiopathic sideroblastic anemia (AISA). We found no metaphases containing the 13q- abnormality in preparations of phytohemagglutinin (PHA)-stimulated lymphocytes from either patient. In both cases, however, some metaphases from Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines contained the clonal karyotypic abnormality. These observations indicate that B lymphocytes but not T cells are expressed as members of the clonal cohort of cells. Our results strongly suggest that the initial pathogenetic events that led to expansion of the 13q- clone occurred in a progenitor cell capable of giving rise to both hematopoietic and B lymphoid cells.

scholarly journals Detection of Epstein Barr Virus (EBV) Antigen in Oral Squamous Cell Carcinoma (OSCC) by Immunohistochemistry in Patients from KPK Province of Pakistan.

2021 ◽  
Vol 28 (12) ◽  
pp. 1829-1836
Author(s):  
Sana Ghani ◽  
Fozia Rauf ◽  
Asif Rehman ◽  
Muhammad Irfan ◽  
Fatima Iqbal ◽  
...  
Keyword(s):  
Oral Mucosa ◽  
Oral Epithelium ◽  
Cross Sectional ◽  
Female Ratio ◽  
Barr Virus ◽  
Epithelial Tissues ◽  
Significant Difference ◽  
Group A ◽  
Epstein Barr ◽  
Group B

Objective: To determine the frequency of EBVLMP-1 antigen positivity in OSCC and normal oral squamous epithelial tissues (control) by immunohistochemistry (IHC) and to see the effect of age and gender in both the OSCC and control tissues. Study Design: Descriptive, Cross Sectional, Multicenter study. Setting: Pathology/ Peshawar Medical College (PMC), Peshawar Dental College and Sardar Begum Dental College, Peshawar. Period: April 2018 to September 2018. Material & Methods: Conducted on total 60 samples divided into two groups. Group A:  30 formalin fixed paraffin embedded tissue blocks of OSCC cases and Group B: 30 non neoplastic oral epithelial tissues (control). Both groups A and B slides were stained through immunohistochemistry for EBV LMP-1 monoclonal antigen. Results: 30 cases of OSCC Group A and 30 cases of non-neoplastic oral mucosa Group B were selected for the LMP-1 staining by immunohistochemistry. The mean age of OSCC was 56.5 years (±14.47 Standard deviation) with a range of 20-80 years. Male: Female ratio was 1.3:1 .OSCC commonly involved buccal mucosa. 80% (n=24/30) OSCC cases were grade 1, all the cases of OSCC (100%) showed epithelial positivity for EBV LMP-1 antigen, whole (29/30) cases of non-neoplastic oral mucosa cases showed positivity and there is no statistically significant difference in both Groups A and B. Conclusion: With the findings of EBV positivity in both the OSCC and all of the control cases; it is concluded that EBV does not play an important role in etiology of OSCC. This suggests that the infection by this ubiquitous virus (EBV) occurs at some point in the life of a person leaving LMP, protein latent in the cells of oral epithelium.

scholarly journals Effects of Epstein-Barr Virus Infection on CD19+ B Lymphocytes in Patients with Immunorelated Pancytopenia

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Yang Zhao ◽  
Yihao Wang ◽  
Hui Liu ◽  
Kai Ding ◽  
Chunyan Liu ◽  
...  
Keyword(s):  
B Cells ◽  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
B Lymphocyte ◽  
Enzyme Linked Immunosorbent Assay ◽  
Epstein Barr Virus Infection ◽  
Barr Virus ◽  
Ebv Infection ◽  
Ebv Dna ◽  
Epstein Barr

Objectives. To explore effects of Epstein-Barr virus (EBV) infection on CD19+ B lymphocytes in patients with immunorelated pancytopenia (IRP). Methods. An enzyme-linked immunosorbent assay (ELISA) in vitro diagnostic kit was used to detect EBV capsid antigen- (CA-) IgG and VCA-IgM antibodies in the serum. We analyzed the EBV-DNA copies of CD19+ B lymphocyte by using real-time quantitative polymerase chain reaction (RT-qPCR). CD21, CD23, CD5, CD80, and CD86 receptors on the surfaces of CD19+ B cells were detected by flow cytometry (FCM). The correlation between these receptors and EBV-DNA copies were evaluated. Results. The results revealed that the positive rate of EBVCA-IgM and CD19+ B lymphocyte EBV-DNA copy in the IRP group were significantly higher than those in the control group (P<0.05). CD19+ B lymphocyte EBV-DNA copies were also more abundant in IRP patients than in control subjects (P<0.05). Expression levels of the CD21, CD23, CD5, CD80, and CD86 receptors on the surfaces of CD19+ B cells in IRP patients with anti-EBVCA IgM positivity were significantly higher than those in anti-EBVCA IgM negativity IRP patients (P<0.05). The results revealed that EBV-DNA copy numbers were positively correlated with CD21, CD23, CD5, CD80, and CD86 expression. Conclusions. EBV infection may activate CD19+ B lymphocytes and further disrupt bone marrow hematopoiesis in IRP patients.

Sign in / Sign up

Export Citation Format

Share Document